%0 Journal Article
%A Röhrich, Manuel
%A Syed, Mustafa
%A Liew, Dawn P
%A Giesel, Frederik L
%A Liermann, Jakob
%A Choyke, Peter L
%A Wefers, Annika K
%A Ritz, Thomas
%A Szymbara, Marina
%A Schillings, Lisa
%A Heger, Ulrike
%A Rathke, Hendrik
%A Kratochwil, Clemens
%A Huber, Peter E
%A von Deimling, Andreas
%A Debus, Jürgen
%A Kauczor, Hans-Ulrich
%A Haberkorn, Uwe
%A Adeberg, Sebastian
%T 68Ga-FAPI-PET/CT improves diagnostic staging and radiotherapy planning of Adenoid Cystic Carcinomas - imaging analysis and histological validation.
%J Radiotherapy and oncology
%V 160
%@ 0167-8140
%C Amsterdam [u.a.]
%I Elsevier Science
%M DKFZ-2021-01009
%P 192-201
%D 2021
%Z 2021 May 1;160:192-201
%X Adenoid cystic carcinomas (ACCs) are rare epithelial tumors mostly situated in the head and neck region and characterized by infiltrative growth. The tumor stroma of ACCs includes cancer-associated fibroblasts (CAFs) expressing Fibroblast Activation Protein (FAP), a new target for positron emission tomography (PET) imaging. Here we describe the value of PET/ computed tomography (PET/CT) imaging using 68Ga-labelled FAP-Inhibitors (68Ga-FAPI-PET/CT) and their clinical potential for staging and radiotherapy planning in 12 ACC patients (7 primary, 5 recurrent).Patients underwent contrast enhanced staging CT (ceCT) and magnetic resonance imaging (ceMRI) before 68Ga-FAPI - PET/CT. PET-scans were acquired 10, 60 and 180 minutes after administration of 150-250 MBq of 68Ga-labelled FAPI tracers. SUVmax and SUVmean values of ACCs and healthy organs were obtained using a 60
%K ACC (Other)
%K Adenoid cystic carcinoma (Other)
%K FAP (Other)
%K Fibroblast Activation Protein (Other)
%K Positron Emission Tomography (Other)
%K Radiotherapy (Other)
%K Staging (Other)
%K TNM (Other)
%K alpha SMA (Other)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:33940087
%R 10.1016/j.radonc.2021.04.016
%U https://inrepo02.dkfz.de/record/168701